Q2 2025 Medivir AB Earnings Call Transcript
Key Points
- Medivir AB (STU:MVR0) presented final data from the Phase Ib/IIa study with Fostrox + Lenvima, showing a patient benefiting from treatment for three years, which is significant for second-line liver cancer.
- The combination of Fostrox + Lenvima maintains a frontrunner position in second-line liver cancer treatment, as confirmed by recent congresses.
- Patent protection for Fostrox + Lenvima was approved in Japan, extending protection until 2041, which strengthens the company's patent strategy.
- The company has a strong support from its largest shareholder, Linc, which provided a SEK30 million loan facility, ensuring financial stability in the short term.
- Medivir AB (STU:MVR0) is actively preparing for a Phase IIb study, with ongoing investments in CMC, indicating readiness to advance clinical development once financing is secured.
- Medivir AB (STU:MVR0) faces financial challenges, with a cash balance of SEK38 million and an estimated cash runway only until the end of Q4 2025.
- The company is in active discussions to secure financing for the next steps, indicating uncertainty in funding for future developments.
- External expenses increased slightly from Q1 due to CMC investments, which could strain financial resources if not managed carefully.
- The return of birinapant from IGM Biosciences after their acquisition by Concentra indicates potential setbacks in partnership opportunities.
- The oncology funding and deal environment remains tough, which could impact Medivir AB (STU:MVR0)'s ability to secure necessary financing.
Welcome to Medivir Q2 report 2025. (Operator Instructions) Now, I will hand the conference over to CEO, Jens Lindberg; and CFO, Magnus Christensen. Please go ahead.
Thank you. Welcome, everyone, to our Q2 report here at Medivir, and we look forward to walking through progress we've seen in Q2 and to address key questions as we continue our preparations for the Phase IIb study with Fostrox and Lenvima.
If we look back at Q2 or if we look even further than that, so to start, we presented final data from the now closed Phase Ib/IIa study with Fostrox + Lenvima in Q1. And interestingly, basically as of today or one of these days, the patient who has been longest on treatment has now been treated with continued benefit for three years, which is a very, very long time for second-line liver cancer patient.
What we also do, we continue to follow what's happening competitively in the second-line liver cancer space, especially when there are new data presentations at major congresses. And Q2 saw two
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
